Trials / Active Not Recruiting
Active Not RecruitingNCT04877717
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with advanced solid cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1904 | SHR-A1904 |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2021-05-07
- Last updated
- 2025-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04877717. Inclusion in this directory is not an endorsement.